Novartis

Title	Published Date
Phase III study shows Novartis drug Afinitor® more than doubles time without tumor growth	02 July 2010
FDA approves Tasigna® for newly diagnosed chronic myeloid leukemia patients	22 June 2010
FDA advisory committee recommends approval of Novartis investigational treatment FTY720	14 June 2010
Novartis announces extension of US regulatory priority review period for FTY720	28 May 2010
Ranibizumab significantly more effective than standard of care in treating vision loss due to DME	24 May 2010
Novartis healthcare portfolio generates strong growth in first quarter of 2010	27 April 2010
Sandoz to acquire Oriel Therapeutics, gaining rights to portfolio of respiratory products	20 April 2010
A potential first-in-class, once-daily oral therapy for relapsing forms of multiple sclerosis	14 April 2010
Novartis receives FDA approval of Menveo®	23 February 2010
Novartis gains exclusive rights to Debio 025	11 February 2010

Didn't we got you connected? If not, please note the following magic buttons:
Facebook
Twitter
LinkedIn
RSS